112 stories
FDA coverage on Peptide News Digest follows the agency's actual paper trail: approval letters, warning letters, PCAC meeting minutes, 503A bulks list rulings, draft guidance, and Citizen Petitions on substances ranging from semaglutide to BPC-157.
The center of gravity in 2025 and 2026 has been compounding. Once GLP-1 shortages resolved, the agency turned to enforcement — 503A patient-specific compounding versus 503B outsourcing, which APIs sit on which list, what counts as a 'clinical need,' and whether additive formulations count as new drugs. The April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is the most consequential single move so far.
Outside GLP-1, the FDA has been active on peptide-vendor warning letters, advisory committee votes (PCAC, Endocrinologic and Metabolic Drugs), and the long grind of Section 503A's bulks list. Browse the latest below.
The FDA published updated guidance clarifying compounding requirements now that semaglutide and tirzepatide shortages have been resolved. The statement reaffirmed enforcement deadlines for 503A and 503B pharmacies while acknowledging ongoing legal challenges from the Outsourcing Facilities Association.
CNN published a comprehensive consumer guide distinguishing FDA-approved peptide therapeutics from unregulated wellness peptides. Experts warn that rising demand is fueling an online black market with unknown safety risks, while HHS Secretary RFK Jr. pushes to relax restrictions.
ProPublica published a major investigation into the FDA's planned reversal on 19 restricted peptides, warning that reclassification under HHS Secretary RFK Jr. could expose consumers to inadequately tested drugs. The Alliance for Pharmacy Compounding acknowledged it knows little about the safety of individual peptides being sold to the public.
A federal grand jury indicted Utah osteopathic physician Justin Bradley Watkins for obtaining non-FDA-approved peptides including tirzepatide, semaglutide, BPC-157, and retatrutide from a Chinese supplier, affixing fake labels, and selling them to over 200 patients without disclosing their unapproved status.
The FDA granted Apotex Corp. the first-ever tentative approval for a generic semaglutide injection equivalent to Ozempic/Wegovy. Actual market entry is blocked by Novo Nordisk patents until ~2032, but the milestone proves a complex peptide injectable can meet FDA generic equivalence standards.
Novo Nordisk received accelerated FDA approval for Wegovy HD, a higher-dose injectable semaglutide offering ~21% weight loss, with aggressive discount pricing to fight Lilly's market share gains.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
The FDA is intensifying enforcement against compounding pharmacies selling unapproved GLP-1 products, threatening seizure and injunction. Hims & Hers was specifically named following the February 2026 TrumpRx launch.
Semaglutide injections officially removed from the FDA drug shortage list, though localized availability issues persist. Tirzepatide shortage status remains contested by the Outsourcing Facilities Association.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.
A Utah physician was indicted for importing and selling misbranded drugs from China to over 200 patients. Customs separately seized 5,000 unapproved peptide units at the border.
The FDA published warning letters targeting companies marketing GLP-1 receptor agonists without regulatory approval, addressing CGMP violations and clinical trial protocol failures.
Three former officials maintain the 2023 decision to deem 19 peptides unsafe for compounding was grounded in documented safety concerns, countering Kennedy's claims on Joe Rogan.
The FDA announced steps to restrict compounded GLP-1 products, specifically naming Hims & Hers. Novo Nordisk has also sued Hims & Hers over compounded semaglutide.
ProPublica reveals the potential reversal of the FDA's 2023 ban on 19 compounded peptides. Three former FDA officials, including former acting commissioner Janet Woodcock, say RFK Jr. mischaracterized their work and that documented safety concerns supported the ban.
Foundayo became the first new molecular entity cleared under the Commissioner's National Priority Voucher Program, with review completed 294 days before the PDUFA date. Commercial pricing set at $25/month insured and $149/month self-pay at the lowest dose.
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.